Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
Terpos, Evangelos, Zambello, Renato, Leleu, Xavier, Kuehr, Thomas, Badelita, Sorina N, Katodritou, Eirini, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Caers, Jo
Published in Cancers (28.10.2022)
Published in Cancers (28.10.2022)
Get full text
Journal Article
Web Resource
Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
Leleu, Xavier, Katodritou, Eirini, Kuehr, Thomas, Terpos, Evangelos, Caers, Jo, Zambello, Renato, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Badelita, Sorina N.
Published in EJHaem (01.02.2023)
Published in EJHaem (01.02.2023)
Get full text
Journal Article
Web Resource
P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study
Terpos, Evangelos, Caers, Jo, Badelita, Sorina N, Zambello, Renato, Kuehr, Thomas, Katodritou, Eirini, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Leleu, Xavier
Published in Clinical lymphoma, myeloma and leukemia (01.10.2021)
Published in Clinical lymphoma, myeloma and leukemia (01.10.2021)
Get full text
Journal Article
MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Richardson, Paul G., Badelita, Sorina N., Besemer, Britta, Boudreault, Jean-Samuel, Byun, Ja Min, Cerchione, Claudio, Gatt, Moshe E., Gibbs, Simon, Koroda, Junya, Martinez-Lopez, Joaquín, Min, Chang-Ki, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Weisel, Katja, Zhou, Xin, Amatangelo, Michael, Wang, Yue, Hwang, Soo Jeong, Emerson, Joshua, Koo, Phillip, Rocci, Alberto, Katz, Jessica
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Richardson, Paul G., Badelita, Sorina N., Besemer, Britta, Boudreault, Jean-Samuel, Byun, Ja Min, Cerchione, Claudio, Gatt, Moshe E., Gibbs, Simon, Koroda, Junya, Martinez-Lopez, Joaquín, Min, Chang-Ki, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Weisel, Katja, Zhou, Xin, Amatangelo, Michael, Wang, Yue, Hwang, Soo Jeong, Emerson, Joshua, Koo, Phillip, Rocci, Alberto, Katz, Jessica
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article